Patents Assigned to Universite de Montpellier
  • Patent number: 11905338
    Abstract: The present invention relates to new peptides comprising an amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, and n=10 to 12, and wherein [X]n comprises 4 R, 4 L and between 2 and 4 W, that may be used as cell-penetrating peptides. The present invention also relates to nanoparticles comprising a peptide of the invention and a cargo molecule and uses thereof.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 20, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Sébastien Deshayes, Karidia Konate, Eric Vives, Gudrun Aldrian, Prisca Boisguerin
  • Publication number: 20240021315
    Abstract: The present invention is drawn to a new diagnosis method and a calculator for predicting the risk of developing a breast late effect (BLE), which is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration, in a subject after radiotherapy (RT), by using Radiation Induced late effect using T-Lymphocyte Apoptosis (RILA) and clinical parameters. The invention is also drawn to diagnosis kits for the implementation of the method and a nomogram.
    Type: Application
    Filed: August 31, 2017
    Publication date: January 18, 2024
    Applicants: INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: David Azria, Sophie Gourgou
  • Publication number: 20240003870
    Abstract: A method of selecting T cells with improved anti-cancer activity, the method including: a) quantifying glucose transporter 1 (GLUT1) expression level at the cell surface of a population of T cells by using a GLUT1 ligand, b) selecting T cells having a low GLUT1 expression level, wherein the T cells having a low GLUT1 expression level have improved anti-cancer activity. Also, a population of T cells with improved anti-cancer activity for use in the treatment of cancer, to the use of a GLUT1 ligand for selecting T cells with improved anti-cancer activity, and to the use of GLUT1 as a biomarker of the anti-cancer therapeutic efficacy of T cells.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 4, 2024
    Applicants: METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, THE UNITED STATES OF AMERICA ,ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Naomi TAYLOR, Marie Charlotte Chantal POUZOLLES, Valérie DARDALHON, Vincent PETIT
  • Patent number: 11852580
    Abstract: A sensor for photoacoustic spectroscopy including a support and a mechanical resonator fastened to the support, including at least one sensor element designed to be vibrated by an acoustic wave, and at least one first capacitive electrode mechanically coupled to the sensor element so as to be moved by the sensor element when it is vibrated; and at least one second capacitive electrode forming with the at least one first electrode, a capacitive sensor; the support facing the sensor element, an apertured part formed by one or more through-openings. Also provided is a detection and/or measurement device and method, for photoacoustic spectroscopy, using such a sensor.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: December 26, 2023
    Assignees: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Aurore Vicet, Kaim Chamassi, Michaël Bahriz
  • Patent number: 11827637
    Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: November 28, 2023
    Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Université De Montpellier
    Inventors: Cédric Bories, Loïc Mathieu, Jean-François Guichou, Muriel Gelin, Aurélien Biechy
  • Patent number: 11821044
    Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 21, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCHE MÈDICALE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Alain Thierry, Safia El Messaoudi
  • Publication number: 20230364431
    Abstract: An active implantable medical device including, once implanted, a module external to the patient and a module inside the patient, the external module and the internal module being intended to transfer energy and data from one to the other. Also, a method for transferring energy and data, the method being implemented by the active implantable medical device.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 16, 2023
    Applicants: NEURINNOV, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INRIA - INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: David ANDREU, David GUIRAUD, Brice SORLI, Arnaud VENA
  • Patent number: 11814686
    Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: November 14, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTÉDE LA RECHERCHE MÉDICALE, UNIVERSITÉ de MONTPELLIER, INSTITUT RéGIONAL DU CANCER DE MONTPELLIER
    Inventors: Alain Thierry, Cynthia Sanchez
  • Patent number: 11746065
    Abstract: A method for manufacturing a part made of composite material in which an adhesion promoter is grafted to a coating present on the fibre surface as well as to a ceramic precursor resin. Afterwards, a ceramic matrix phase is formed in the porosity of the fibre preform by pyrolysis of the polymerised resin.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: September 5, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SAFRAN CERAMICS, UNIVERSITE DE BORDEAUX, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Nicolas Eberling-Fux, Marion France Hélène Schmidt, Samuel Jean-Charles Bernard
  • Patent number: 11746060
    Abstract: A method for manufacturing a part made of composite material includes forming a ceramic matrix phase in pores of a fibrous preform by pyrolysis of a cross-linked copolymer ceramic precursor, the cross-linked copolymer including a first precursor macromolecular chain of a first ceramic having free carbon, and a second precursor macromolecular chain of a second ceramic having free silicon, the first macromolecular chain being bonded to the second macromolecular chain by cross-linking bridges including a bonding structure of formula *1—X—*2; in this formula, X designates boron or aluminium, -*1 designates the bond to the first macromolecular chain and -*2 the bond to the second macromolecular chain.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: September 5, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SAFRAN CERAMICS, UNIVERSITE DE BORDEAUX, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Marion France Hélène Schmidt, Samuel Jean-Charles Bernard, Nicolas Eberling-Fux
  • Patent number: 11739073
    Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: August 29, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Julien Santo, Cécile Apolit
  • Patent number: 11708364
    Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: July 25, 2023
    Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
    Inventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
  • Publication number: 20230220480
    Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.
    Type: Application
    Filed: November 6, 2020
    Publication date: July 13, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
  • Publication number: 20230218605
    Abstract: The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, an ASD obtainable by specific processes, their use as a medicament and more particularly their use in the treatment and/or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.
    Type: Application
    Filed: January 29, 2021
    Publication date: July 13, 2023
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme MENEGOTTO, Jérôme DENIS
  • Patent number: 11690535
    Abstract: A mobile music listening device synchronizing in a personalized way music and movement, and dedicated to improving the kinematics of the runner. Thanks to inertial units connected to a smartphone, the runner's steps are detected in real time by the mobile application. A dedicated algorithm adapts the pulsation of the musical excerpts in such a way as to bring the runner to a suitable cadence, capable of preventing injuries. A method for the synchronization of the rhythmic stimulation with the biological variability using a Kuramoto model characterized in that phase oscillator with a coupling term from the movement dynamics with parameters of, coupling strength, maximum and minimum frequencies for a fraction of the unmodified song frequency, maximum difference between the tempo and target frequency, Target the target frequency.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: July 4, 2023
    Assignees: UNIVERSITEIT GENT, CENTRE HOSPITALIER ET UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIER, CLINIQUE BEAU-SOLEIL, MAYNOOTH UNIVERSITY
    Inventors: Benoît Bardy, Simone Dalla Bella, Loic Damm, Dobri Dotov, Déborah Varoqui, Jeska Buhmann, Marc Leman, Bart Moens, Edith Van Dyck, Sean O'Leary, Joseph Timoney, Rudi Villing, Tomas Ward, Valérie Cochen de Cock
  • Patent number: 11678679
    Abstract: A meat analogue may include a macrostructure of connected sheared fibers oriented parallel to one another and gaps positioned between the sheared fibers. The macrostructure may include meat and may include a vegetable protein. An extrusion system may include an extruder and a die. The extrusion system may produce a meat analogue. A meat analogue may include an animal protein. The extruder may be connectable to the die. The extrusion system may be configured to direct a material including an animal protein from the extruder to the die and through a fluid path extending through the die. The die may be configured to inject a fat or a fat analogue into the material such that the fat or the fat analogue is embedded but visually distinct from the material including the animal protein when the fat or the fat analogue and the material exit the die.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 20, 2023
    Assignees: SOCIÉTÉ DES PRODUITS NESTLÉ S.A., UNIVERSITE DE MONTPELLIER, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
    Inventors: Patrick Pibarot, Christophe Joseph Etienne Schmitt, Christian Sanchez, Marie-Héléne Morel
  • Patent number: 11673912
    Abstract: A continuous, solvent-free and non-enzymatic method for synthesizing a compound of formula (I): Ra-POLYPEP-Rc (I) wherein: POLYPEP is a poly-amino acid compound, Ra and Rc are as specified, the method including the steps of: a) feeding an extrusion reactor with (1) a compound of formula (II) Ra-PEPNt-Rg (II) wherein; PEPNt is a mono- or a poly-amino acid compound, Ra and Rg are as specified, and (2) a compound of formula (III) H-PEPCt-Rc (III) wherein: PEPCt is a mono- or a poly-amino acid compound, and Rc is as defined in the absence of any solvent, so that the compound of formula (II) and the compound of formula (III) react together for generating a compound of formula (I), and b) collecting the compound of formula (I) from the extrusion reactor.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: June 13, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, ECOLE DES MINES D'ALES, ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS
    Inventors: Yves Yeboue, Benjamin Gallard, Nicolas Le Moigne, Frédéric Lamaty, Jean Martinez, Thomas-Xavier Metro
  • Publication number: 20230175068
    Abstract: A method for in vitro prognosis of the outcome of an individual afflicted by an acute myeloid leukaemia. The method includes the following steps: (a) measuring the expression level of genes involved in 5 DNA repair pathways, (b) calculating a score value for each DNA repair pathway group of genes, and (c) classifying the individual as having a good or a bad outcome.
    Type: Application
    Filed: April 14, 2021
    Publication date: June 8, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIER
    Inventors: Jérôme MOREAUX, Ludovic GABELLIER, Caroline BRET
  • Patent number: 11649211
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Patent number: 11649210
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman